Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BGLC

BGLC - Bionexus Gene Lab Corp. Stock Price, Fair Value and News

$2.90+0.18 (+6.62%)
Market Closed

51/100

BGLC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

51/100

BGLC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.29

Target 3M

$3.16

Target 6M

$3.2

BGLC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BGLC Price Action

Last 7 days

-5.5%

Last 30 days

-29.1%

Last 90 days

-44.1%

Trailing 12 Months

-27.5%

BGLC RSI Chart

BGLC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BGLC Valuation

Market Cap

5.2M

Price/Earnings (Trailing)

-2.27

Price/Sales (Trailing)

0.55

EV/EBITDA

-3.22

Price/Free Cashflow

-1.89

BGLC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.29

Target 3M

$3.16

Target 6M

$3.2

BGLC Fundamentals

BGLC Revenue

Revenue (TTM)

9.5M

Rev. Growth (Yr)

-3.29%

Rev. Growth (Qtr)

12.55%

BGLC Earnings

Earnings (TTM)

-2.3M

Earnings Growth (Yr)

47.3%

Earnings Growth (Qtr)

-15.06%

BGLC Profitability

Operating Margin

14.77%

EBT Margin

-25.05%

Return on Equity

-33.7%

Return on Assets

-30.14%

Free Cashflow Yield

-53%

BGLC Investor Care

Buy Backs (1Y)

0.01%

Diluted EPS (TTM)

-0.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20259.3M9.6M9.5M0
20249.8M9.2M9.3M9.5M
202310.3M10.4M10.3M9.8M
202212.9M12.3M11.3M10.9M
202111.8M13.8M14.2M13.4M
202000011.4M
20190000
2018000212.3K
Get all data in R, Python etc through our Historical Stock Data APIs

About Bionexus Gene Lab Corp.

BGLC
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
 CEO
 WEBSITEbionexusgenelab.com
 SECTORBasic Materials
 INDUSTRYSpecialty Chemicals
 EMPLOYEES27

Bionexus Gene Lab Corp. Frequently Asked Questions

BGLC is the stock ticker symbol of Bionexus Gene Lab Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Bionexus Gene Lab Corp. is 5.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BGLC's fair value in chart for subscribers.

The fair value guage provides a quick view whether BGLC is over valued or under valued. Whether Bionexus Gene Lab Corp. is cheap or expensive depends on the assumptions which impact Bionexus Gene Lab Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BGLC.

As of Wed Jan 28 2026, BGLC's PE ratio (Price to Earnings) is -2.27 and Price to Sales (PS) ratio is 0.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BGLC PE ratio will change depending on the future growth rate expectations of investors.